Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

The purpose of the study is to see whether adding GB-0895 can lower the number of serious asthma attacks over a one‑year period. Volunteers will receive the assigned injection at regular intervals for about 52 weeks and will attend routine visits where doctors will check lung function using simple breathing tests, ask about daily symptoms, and have participants fill out questionnaires that measure how asthma affects daily life and overall well‑being. Terms such as “subcutaneous” mean the medication is delivered under the skin, and “systemic corticosteroids” refer to steroid medicines taken by mouth or injection that help reduce inflammation during severe attacks.

The purpose of the study is to see if this combination medication is safe for the heart and blood vessels and whether it can help prevent serious heart-related problems. The study will look at how many people experience major heart events such as heart-related death, heart attack, or stroke. The study will also look at changes in body weight, blood pressure, cholesterol levels, and blood sugar control. For people with diabetes, the study will check their HbA1c, which is a measure of average blood sugar over time.

During the study, people will receive weekly injections for up to several months. The study will collect information about any side effects and will measure various health markers through blood tests and physical examinations. The study will also assess quality of life, sleep quality, and pain levels. For people with diabetes, the study will monitor for episodes of very low blood sugar. The study will track kidney function by measuring eGFRcr, which shows how well the kidneys are filtering waste from the blood, and will check protein levels in urine. The study will continue until enough information is gathered to determine whether the medication is effective and safe.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The study aims to determine which treatment combination is more effective at preventing the disease from getting worse. Patients will receive either tablets of sonrotoclax or venetoclax to take by mouth, along with infusions of obinutuzumab or rituximab given through a vein. The medications will be given over several months according to a specific schedule.

Throughout the study, doctors will monitor how well the treatments work by performing various tests and examining patients regularly. They will check for the presence of cancer cells in the blood, measure how long patients live without their disease getting worse, and track any side effects that may occur. The study is expected to continue until the end of 2031.

The purpose of the study is to compare the effectiveness and safety of the two treatments in reducing the need for red blood cell transfusions. Participants are randomly assigned to receive either elritercept or epoetin alfa and will be treated for up to 24 weeks. During this time, they will have regular clinic visits where blood samples are taken to check hemoglobin levels, which indicate how well the blood is carrying oxygen, and doctors will record whether transfusions are still needed.

The study involves a series of visits scheduled roughly every few weeks. At each visit, a healthcare professional will administer the injection, perform a quick blood test, and ask about any side effects. The overall goal is to see if participants can stay without transfusions for a sustained period while their hemoglobin improves.

The comparison group receives the standard treatment, which consists of several different medications including rituximab, doxorubicin hydrochloride, vincristine, cyclophosphamide, and prednisolone. In the study group, participants receive pirtobrutinib as an oral tablet and epcoritamab as a subcutaneous injection, which is a method of delivering medication just under the skin. The study aims to determine how well these different treatment options work to control the disease.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

The purpose of this study is to compare how well the combination of STK-012 with chemotherapy works compared to chemotherapy alone in people whose cancer has a specific characteristic related to a marker called PD-L1. The study will look at how many people respond to the treatment, meaning their tumors shrink or disappear. During the study, participants will receive their assigned treatment over a period of time, with regular check-ups to monitor how the cancer is responding and to check for any side effects. The study will also measure how long people live without their cancer getting worse and how long they live overall. Blood tests and other assessments will be done to understand how the experimental medicine works in the body and whether it causes the body to produce antibodies against it.

This study is designed for people who have advanced lung cancer that has spread to other parts of the body or cannot be treated with surgery or radiation. Participants must not have received previous treatment for their advanced cancer, although they may have had treatment after surgery if it was completed more than six months before joining the study. The study will include people whose tumors do not have certain genetic changes for which other standard treatments are available. Participants will need to be well enough to carry out normal daily activities and have adequate organ function based on blood tests.

The purpose of this study is to find out if Linvoseltamab can eliminate the abnormal plasma cells that might turn into multiple myeloma and to determine the safest and most effective dose to use. The study will also look at how well people tolerate the medication and whether it causes any unwanted effects. In the first part of the study, different dose levels of Linvoseltamab will be tested in small groups to identify the highest dose that can be given safely. In the second part, a larger group of people will receive the selected dose to see how well it works at causing a complete response, which means the abnormal cells can no longer be detected.

During the study, participants will receive Linvoseltamab through infusions over a period of up to 27 months. Doctors will monitor participants closely for any side effects and will check blood samples to see if the treatment is working. The study will measure whether participants achieve a complete response, meaning all signs of the abnormal cells have disappeared, and whether this response lasts over time. Other measurements will include checking for minimal residual disease, which looks for very small amounts of abnormal cells that may still be present, and tracking how long people remain free from the disease getting worse. Blood tests will also be done to measure the amount of Linvoseltamab in the body and to check if the body develops antibodies against the medication.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

Participants will be randomly assigned to receive either povetacicept or tacrolimus. The study will last up to 72 weeks, during which time participants will receive their assigned treatment and attend regular visits for monitoring. During these visits, various tests will be performed to check kidney function, measure protein levels in the urine, and monitor overall health. Blood tests, heart tracings, and other measurements will be taken to ensure the treatments are working properly and to watch for any unwanted effects.

The main goal is to see how many participants achieve complete remission of their kidney disease, which means their kidney function has improved and the amount of protein in their urine has decreased to normal or near-normal levels. The study will also look at different definitions of improvement and will carefully track any side effects or health changes that occur during treatment. This information will help doctors understand whether povetacicept could be a useful treatment option for people with this type of kidney disease.

The purpose of this study is to find out how well CagriSema works in helping people lose weight compared to placebo, when used together with diet and exercise changes. The study will also look at whether people can achieve certain weight loss goals, such as losing at least five percent or twenty percent of their body weight. Additionally, the study will examine how the treatment affects waist size, blood sugar control measured by a test called HbA1c, blood pressure, and quality of life related to physical function. The safety of the treatment will be carefully monitored by tracking any unwanted effects that occur during the study, including episodes of low blood sugar.

During the study, participants will receive their assigned treatment for up to one year. Throughout this time, they will have regular visits where doctors will check their weight, blood sugar levels, blood pressure, and overall health. The study will collect information about how the treatment affects the body and whether it causes any side effects. This research aims to provide information about whether this combination treatment could be a helpful option for people with type 2 diabetes who are also struggling with excess weight.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The purpose of this research is to assess how well two different doses of CYB003 work compared to placebo in treating adults with depression. The study medication will be given twice over a period of several weeks, with participants receiving either CYB003 capsules (8 mg or 16 mg) or placebo capsules. Throughout the study, participants will continue taking their current antidepressant medication.

During the trial, participants will attend multiple clinic visits where their depression symptoms will be evaluated using various assessment tools. The study will track changes in depression symptoms over 84 days to determine if the treatment is effective. The medication’s safety will also be monitored throughout the study period.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The study aims to compare how well RMC-6236 works compared to docetaxel in treating patients whose cancer has a specific genetic change called RAS mutation. These are changes in genes that can affect how cancer grows and responds to treatment. The study is specifically designed for patients who have already received previous cancer treatments.

During the study, patients will be randomly assigned to receive either RMC-6236 tablets daily or docetaxel infusions. The treatment may continue for up to 20 months, depending on how well the patient responds to the medication and whether any side effects occur. The study will track how the cancer responds to treatment and how long patients live without their cancer getting worse.

The treatment involves receiving TORL-1-23 through an intravenous infusion (given directly into a vein). During the study, participants may also receive pegfilgrastim, a supportive medication that helps the body produce white blood cells after treatment. The study treatment may continue for up to 24 months, depending on how well participants respond to the therapy.

The study medication TORL-1-23 is designed to specifically target cancer cells that have the CLDN6 protein on their surface. It works by delivering a cancer-fighting substance directly to these cells while aiming to minimize effects on healthy cells. This targeted approach represents a new way of treating these types of cancer that no longer respond to standard platinum-based treatments.

The study is designed as a long-term extension trial, which means it continues to follow participants who have completed previous studies of the same medication. During the trial, participants may receive up to three additional doses of CYB003 while continuing their regular antidepressant medication. The maximum daily dose of the study medication is 16 milligrams, and the treatment period can last up to 43 days.

Throughout the study, researchers will monitor how well participants maintain their improvement in depression symptoms and how quickly symptoms might return, if at all. They will also track whether participants who didn’t respond well to the initial treatment might benefit from additional doses. The study will evaluate both the safety of the medication and how well it works over a longer period.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

The purpose of the study is to compare the effectiveness of Rilvegostomig with Pembrolizumab in treating patients with a specific type of lung cancer that has spread to other parts of the body and shows high levels of a protein called PD-L1. The study will look at how long patients live and how long they live without the cancer getting worse. Participants will receive either Rilvegostomig or Pembrolizumab as their first treatment for this type of lung cancer. The study will monitor patients over time to see how well the treatments work and to check for any side effects.

Throughout the study, researchers will collect information on how the treatments affect overall survival, which is the length of time patients live after starting the treatment, and progression-free survival, which is the time patients live without the cancer worsening. Other aspects being studied include the response rate to the treatments, the duration of the response, and any side effects experienced. The study aims to provide valuable information on the potential benefits and risks of using Rilvegostomig compared to Pembrolizumab for treating this type of lung cancer.

The purpose of the study is to see if the intradermal booster dose is as effective as the subcutaneous booster dose in creating an immune response, which is the body’s way of defending against infections. Participants in the study will receive either the intradermal or subcutaneous booster dose, and their immune response will be monitored over time. The study will also look at the safety of the vaccine and any side effects that may occur.

Participants will be followed for a period of time to assess their immune response at different intervals, such as one month and six months after receiving the booster dose. The study will also monitor for any serious side effects and the occurrence of any breakthrough infections, which are infections that occur despite vaccination. The trial aims to provide valuable information on the best way to use the MVA-BN vaccine to protect against mpox.

The purpose of the study is to evaluate how effective and safe these two treatment combinations are for patients with newly diagnosed multiple myeloma. Participants in the study will be randomly assigned to receive one of the two treatment combinations. The study will monitor the participants over time to see how their disease responds to the treatment and to check for any side effects. The study will also look at how long the participants live without their disease getting worse and other health-related outcomes.

During the study, participants will receive their assigned treatment and will have regular check-ups to monitor their health and the progress of their disease. The study will continue for several years to gather enough information to determine which treatment combination is more effective and safer for patients with multiple myeloma. This research aims to improve treatment options for people with this type of cancer.

The purpose of the study is to determine if adding venetoclax to the treatment with ivosidenib and azacitidine can improve outcomes for patients with newly diagnosed IDH1-mutated AML who are not eligible for intensive chemotherapy. The study will involve taking these medications in the form of film-coated tablets or injections over a period of time. Some patients will receive a placebo, which looks like the real medication but does not contain the active drug, to compare the effects.

Participants in the study will be monitored to see how their condition responds to the treatment. The study will track how long patients remain free of disease progression, as well as other factors like overall survival and quality of life. The trial aims to provide valuable information on whether this combination of medications can offer a new treatment option for patients with this specific type of AML.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

The purpose of the study is to compare two approaches to hormone therapy: intermittent maximum androgen blockade (iMAB) and continuous maximum androgen blockade (cMAB). The study aims to determine the benefits and risks of these approaches in patients who have shown a significant response to initial hormone therapy. Participants will be randomly assigned to either continue their hormone therapy without interruption or to have breaks in their treatment. The study will monitor how long patients can go without restarting hormone therapy and compare the overall survival rates between the two groups.

Throughout the study, participants will be observed for changes in their quality of life, including physical functioning, sexual activity, and pain levels. The study will also track the time it takes for patients to need additional prostate cancer treatments and monitor their testosterone and PSA (prostate-specific antigen) levels. The trial will help determine if taking breaks in hormone therapy can maintain the same level of cancer control as continuous treatment while potentially improving the quality of life for patients.

The purpose of the study is to compare the effectiveness of these treatments in patients who have not received prior treatment for their CLL or SLL. The study will look at how long patients live without their disease getting worse, which is known as progression-free survival. The trial will also explore how the treatment duration can be adjusted based on the measurement of individual residual disease, which refers to the small number of cancer cells that might remain after treatment.

Participants in the study will receive one of the treatment combinations for a set number of cycles. The study will monitor various outcomes, including the overall response to the treatment, the duration of the response, and the time until the next treatment is needed. Safety will also be closely monitored by tracking any adverse events. The study aims to improve treatment outcomes by tailoring the duration of therapy to each patient’s needs.

The purpose of the study is to determine if this combination of medications can help improve the overall survival of patients with this specific type of AML. Participants in the study will receive either the combination of Revumenib, Azacitidine, and Venetoclax or a placebo along with Azacitidine and Venetoclax. The study will last for a period of up to 76 weeks, during which the effects of the treatment will be monitored. The medications will be administered in the form of tablets taken orally, and Azacitidine will be given as an injection.

This trial aims to provide valuable information on whether the addition of Revumenib can enhance the effectiveness of the existing treatment for patients with these specific genetic changes in AML. The study will also look at various outcomes, such as the time it takes for the treatment to start working, the duration of the response, and the quality of life of the participants. The results will help in understanding the potential benefits and safety of this new treatment approach for patients with AML who cannot undergo intensive chemotherapy.

Participants in the study will receive either benralizumab or a different treatment approach involving higher doses of their current asthma medication, which includes inhaled corticosteroids and long-acting beta2 agonists. The study will compare the effectiveness of adding benralizumab to the existing treatment versus increasing the dose of the current medication. The trial will last for a period of 48 weeks, during which the participants’ asthma symptoms and overall health will be closely monitored.

The goal of the study is to determine if benralizumab can help reduce asthma symptoms and improve the quality of life for people with eosinophilic asthma. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for individuals with this specific type of asthma. The study will also assess any potential side effects of benralizumab to ensure its safety for patients.

Participants in the study will receive either semaglutide or a placebo, which is an injection that does not contain any active medication. The study will last for a period of 36 weeks, during which participants will receive regular injections and follow a healthy lifestyle advice program. The trial will monitor changes in blood pressure, body weight, and other health-related factors to assess the effectiveness and safety of semaglutide in managing resistant hypertension and obesity.

The study will also evaluate the acceptability of the treatment by observing any side effects and the number of participants who continue with the treatment. Additionally, the trial will gather information on participants’ quality of life, health beliefs, and medication adherence. The goal is to determine if semaglutide can be a beneficial treatment option for people with obesity and resistant hypertension, potentially leading to better blood pressure control and overall health improvements.

The purpose of the study is to see if the combination of Vedolizumab and Upadacitinib can improve the health of people with moderately to severely active Crohn’s Disease more effectively than Vedolizumab alone. Participants will receive the treatment for a period of up to 52 weeks. Initially, both medications will be used together for a short period to see if they can quickly improve symptoms and the condition of the digestive tract. After this initial phase, the study will continue with Vedolizumab alone to maintain the improvements.

Throughout the study, participants will be monitored to assess their response to the treatment, focusing on both clinical symptoms and the condition of the digestive tract as seen through medical examinations. The study aims to provide valuable information on whether this dual therapy approach can offer better outcomes for individuals living with Crohn’s Disease.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of this research is to determine if tozorakimab can reduce the frequency of COPD flare-ups (also called exacerbations) when added to regular COPD treatments. During the study, some participants will receive tozorakimab while others will receive a placebo, in addition to their regular COPD medications. The study will particularly focus on people who previously smoked and have experienced COPD flare-ups in the past.

The treatment period will last for approximately one year, during which participants will receive regular injections of either tozorakimab or placebo. Throughout the study, participants will continue using their regular COPD medications, including inhalers. The study will monitor how often participants experience COPD flare-ups and track changes in their breathing and overall health.